

# Coverage, Billing, and Financial Assistance

## FOR PATIENTS

### What is genomic profiling?

Genomic profiling is a laboratory test performed on a sample of your tumor tissue to check for unique characteristics that may be driving the growth of your tumor, such as gene mutations (changes) or other biomarkers. Information about genomic alterations that are unique to your individual cancer may help doctors identify treatments designed to target those biomarkers.

### What is Strata Select<sup>™</sup>?

The Strata Select test is a comprehensive genomic profiling test, which means it looks for cancer-related gene mutations and gene expression signatures in your tumor to help identify FDA-approved cancer treatments and clinical trial options that may be right for you. The test may also show that you are already on the best treatment plan or provide insight that other treatments may not be effective.

### Why Strata Select?

Because Strata Select could inform treatment options for you, and it can do so with less tumor tissue than other similar tests.

#### How it Works



**Test ordered**  
Your medical provider orders the Strata Select test.



**Financial assistance**  
Strata will reach out to enroll you in our financial assistance program if you are not covered by Medicare<sup>#</sup>



**Test performed**  
Strata performs the test, and your doctor receives results in a report.



**Billing**  
Strata bills your insurance plan for the Strata Select test.

<sup>#</sup> Once the Strata charge processes through the patient's insurance, remaining patient balances will be billed to the patient in accordance with the patient's insurance plan and after qualified financial assistance has been applied. Patients may apply for financial assistance at any point before, during or after this process. Medicare Part B covers Strata Select in full when medically necessary and Medicare criteria are met. Medicare Advantage plans will cover Strata Select and remit payment in accordance with each patient's individual policy.

## Insurance Coverage

- The Strata Select test is covered by Medicare for qualifying patients.  
Medicare Coverage Criteria: i. Patient has been diagnosed with a solid malignant neoplasm; AND ii. Patient has either recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer (only requires one of these to be met); AND iii. Patient has not been previously tested with the same test using NGS for the same cancer genetic content; AND iv. Patient has decided to seek further cancer treatment (e.g., therapeutic chemotherapy)
- Qualifying patients with Medicare Part B should have no out-of-pocket cost for the Strata Select test.
- Your out-of-pocket cost will depend on your insurance plan. For uninsured or under-insured patients, Strata Oncology offers generous financial assistance to reduce or eliminate out-of-pocket cost for qualified patients in the U.S.

## Strata Cares™ Financial Assistance Program

A Strata Patient Support Specialist will work directly with you and your family to determine if you qualify for financial assistance that may eliminate or substantially reduce your out-of-pocket cost.

- If you would like to apply for our financial assistance program online, visit: <https://www.strataoncology.com/fap>.
- You may enroll in our financial assistance program before, during, or after the testing process. Your final out-of-pocket financial responsibility will be determined after all applicable insurance claims and appeals have been completed.

**Based on U.S. population statistics and current HHS Federal Poverty Guidelines\*, we estimate**

**90%**

of patients would have \$0  
out-of-pocket cost  
for Strata Select testing

**98%**

of patients would have  
out-of-pocket cost of  
\$200 or less  
for Strata Select testing

## Questions?

Contact our billing or financial assistance departments 9 am – 5 pm EST M-F by calling 833.523.0585 and following the prompts or emailing [billing@strataoncology.com](mailto:billing@strataoncology.com) or [stratacares@strataoncology.com](mailto:stratacares@strataoncology.com).

\* Federal Register, Volume 85, No. 12, January 19, 2023, pp. 3424. Specific determination will be made individually.